Please login to the form below

Not currently logged in
Email:
Password:

Judge rules in Amgen's favour over Mircera patent row

A US judge has ruled that Roche's pegylated-erythropoietin (peg-EPO) anaemia drug Mircera (continuous erythropoietin receptor activator) infringes one of biotech company Amgen's patents.

A US judge has ruled that Roche's pegylated-erythropoietin (peg-EPO) anaemia drug Mircera (continuous erythropoietin receptor activator) infringes one of biotech company Amgen's patents.

The judge ruled that Mircera will infringe Amgen's EPO pharmaceutical composition patent number 5,955,422, and in a separate decision the Court also granted summary judgment in favour of Amgen on certain Roche's defences against the patents-in-suit. The court denied requests for summary judgment on the remaining five motions.

The case will now go to trial on September 4 2007, where the court will hear Amgen's claim of infringement for additional patents and also hear Roche arguments on the validity and enforceability of Amgen's patents.

"Amgen continues to believe that its patents are valid and enforceable, and that Roche's peg-EPO product will infringe other Amgen patents relating to recombinant erythropoietin and its production," said Amgen in a statement.

Amgen said it also believes that Mircera "provides no clinical or patient benefit" over Amgen's own therapies, Epogen (epoetin alfa) and Aranesp (darbepoetin alfa).

Analysts from Citigroup said: "We believe that Amgen's case is now stronger since [Judge] Young seems to disagree with Roche's claims  that Mircera is a distinct molecular entity that falls outside the scope of Amgen's claims."

Mircera was approved in the EU in July 2007 but has yet to be approved in the US. According to media reports, Roche  still intends to launch the drug in the US once it is approved by the FDA, despite the ruling.

29th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics